Test Price
2,800 AED✅ Home Collection Available
MOCS1 Gene Molybdenum Cofactor Deficiency Type A Genetic Test | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Diagnostic Accuracy
99.9% sensitivity via ISO 9001:2015 certified NGS processing with AI-optimized variant interpretation (ACMG 2025 standards).
Sample Collection Logistics
VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
Post-Test Support
Complimentary telephonic clinical guidance with a DHA-licensed genetic counselor after result delivery.
Insurance & Billing
Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The MOCS1 gene Next-Generation Sequencing (NGS) test detects pathogenic variants in the MOCS1 gene, confirming Molybdenum Cofactor Deficiency Type A with a diagnostic yield exceeding 99%. Early molecular diagnosis enables timely initiation of cyclic pyranopterin monophosphate (cPMP) therapy, dramatically improving neurodevelopmental outcomes. This test is indicated for symptomatic infants, at-risk family members, and carrier screening.
| Feature | NGS Molecular Test (DNA Labs UAE) | Conventional Metabolic Workup |
|---|---|---|
| Methodology | Next‑Generation Sequencing (NGS) with full MOCS1 gene coverage and AI‑powered variant interpretation | Biochemical assays (sulfite, xanthine, uric acid) – indirect and often inconclusive |
| Diagnostic Sensitivity | 99.9% (confirmed pathogenic variants per ACMG 2025) | ~70% (misses carrier status and atypical phenotypes) |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks (often requires multiple sample types) |
| Clinical Utility | Definitive diagnosis, carrier testing, and pre‑symptomatic family screening | Limited to symptomatic metabolite detection; cannot detect carriers |
Physician Insight & Safety Protocols
“I understand the profound anxiety that accompanies a possible genetic diagnosis for your child. While this NGS test provides robust molecular evidence, interpretation must integrate the full clinical presentation. Always discuss results with a metabolic specialist before initiating any therapy. Genetic counseling for the family is equally critical.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory: Medication Continuation
Do not alter or discontinue any prescribed medications without explicit instruction from your treating physician. This test does not change current treatment plans without specialist consultation.
Patient Exclusion Criteria & Emergency Red Flags
- Active bleeding disorder or local infection at the venipuncture site – postpone sample collection until resolved.
- Known allergy to latex or alcohol swabs – inform the phlebotomist prior to collection.
- Emergency Red Flags:
- Uncontrolled seizures, breathing difficulties, or loss of consciousness – seek immediate emergency medical attention. This test is not a substitute for acute crisis management.
Patient FAQ & Clinical Guidance
1. What is the purpose of the MOCS1 gene test?
This NGS test identifies disease-causing mutations in the MOCS1 gene to confirm Molybdenum Cofactor Deficiency Type A diagnosis. It enables early, targeted treatment with cyclic pyranopterin monophosphate (cPMP) before irreversible neurological damage occurs. The test can also determine carrier status in family members.
2. How is the sample collected for this DNA test?
MOCS1 DNA testing requires a whole blood sample (or extracted DNA/FTA card). Our home collection team uses a simple venipuncture; the sample is immediately stabilized and transported in ISO-certified cold-chain conditions. A pre-test genetic counseling session with a clinical history and pedigree chart is mandatory.
3. What does a positive MOCS1 result mean?
A positive result confirms Molybdenum Cofactor Deficiency Type A and indicates the need for an urgent metabolic specialist consult. Treatment with cPMP should start immediately under expert supervision. Carrier screening for siblings and genetic counseling for future pregnancies are strongly recommended.
UAE Regulatory & Data Privacy Adherence
Your data is protected under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic testing is performed under the clinical safety framework of Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE holds DHA Facility License 1143 and follows strict confidentiality and informed consent protocols.
Clinical & Logistical Metadata
| Test Name | MOCS1 Gene Sequencing (Molybdenum Cofactor Deficiency Type A) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks from sample receipt |
| Sample Type / Matrix | Whole blood (EDTA), extracted DNA, or FTA card – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection |
| Methodology Used | Next-Generation Sequencing (NGS) with full MOCS1 gene coverage, AI-powered variant interpretation per ACMG 2025 |
| ICD-10-CM Code | E83.10 |
| LOINC Code | 94306-0 |
| DHA Facility License & Address | DHA License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians